+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Ascites Market Report and Forecast 2023-2031

  • PDF Icon


  • 147 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797881
The global ascites market size attained a value of USD 2.07 billion in 2022. The market is anticipated to grow at a CAGR of 4.3% during the forecast period of 2023-2031 to attain a value of USD 3.02 billion by 2031.

Ascites Market: Introduction

Ascites is the abnormal accumulation of fluid in the peritoneal cavity, which is the space between the abdominal organs and the abdominal wall. It is a symptom rather than a disease itself and is often associated with underlying medical conditions that affect the liver, heart, kidneys, or other organs. Ascites can be classified as either transudative (caused by changes in pressure within blood vessels) or exudative (caused by inflammation or infection).

The most common cause of ascites is liver cirrhosis, accounting for approximately 80% of cases. Cirrhosis leads to increased pressure in the portal vein system (portal hypertension) and reduced production of albumin, a protein that helps maintain fluid balance within blood vessels. As a result, fluid leaks from blood vessels into the peritoneal cavity.

Other causes of ascites include:

1. Heart failure: Poor heart function can lead to fluid build-up throughout the body, including the peritoneal cavity.
2. Kidney disease: Nephrotic syndrome, a condition characterized by protein loss in the urine, can result in low blood protein levels and fluid accumulation in the abdomen.
3. Cancer: Tumours in the abdomen, such as ovarian or gastrointestinal cancers, can cause inflammation and fluid build-up, leading to exudative ascites.
4. Infection: Peritonitis, an infection of the peritoneal cavity, can lead to inflammation and fluid accumulation.
5. Pancreatitis: Inflammation of the pancreas can cause fluid to leak into the peritoneal cavity.
6. Hypoalbuminemia: Low blood levels of albumin due to malnutrition or liver disease can contribute to fluid accumulation in the abdomen.

In some cases, the underlying cause of ascites may be challenging to determine, requiring further diagnostic tests and evaluations by medical professionals. Treatment for ascites generally involves addressing the underlying cause and may include medications, lifestyle changes, or surgical interventions as appropriate.

Ascites Market Segmentations

The market can be categorised into treatment, diagnosis, route of administration, end user, and region.

Ascites Market Breakup by Treatment

  • Medicinal Therapy
  • Diuretics
  • Antibiotics
  • Surgery
  • Paracentesis
  • Others

Market Breakup by Diagnosis

  • Ascites Ultrasound
  • CT Scan
  • MRI
  • Blood Test
  • Laparoscopy
  • Angiography
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by End User

  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Ascites Market Scenario

The global ascites market is driven by the increasing prevalence of underlying conditions that lead to ascites, such as liver cirrhosis, heart failure, kidney disease, and certain cancers. This market encompasses various aspects, including diagnostic tools, therapeutic interventions, and supportive care services aimed at managing ascites and its complications. The market is influenced by factors such as the aging population, advancements in diagnostic and treatment technologies, and increased awareness of liver diseases and other associated conditions.

Market Drivers

The ascites market is propelled by several factors, including the growing prevalence of liver cirrhosis and other underlying conditions responsible for ascites development. Additionally, the aging population, which is more susceptible to these conditions, contributes to the market's growth. Technological advancements in diagnostic tools, such as imaging modalities and laboratory tests, help detect ascites earlier and more accurately, further driving market growth. Furthermore, the development of novel therapeutic interventions, including new medications and minimally invasive procedures, offers improved treatment options for patients with ascites.

Market Challenges

Despite the growing demand for ascites management, the market faces certain challenges. The high cost of diagnostic tools and treatments may limit access to care, particularly in low- and middle-income countries. Furthermore, the shortage of specialized healthcare professionals, such as hepatologists and gastroenterologists, can hinder effective ascites management in some regions. Additionally, the complexity of managing ascites, especially in patients with advanced liver disease or other comorbidities, poses significant challenges to healthcare providers and patients alike.

Regional Analysis

Geographically, the global ascites market can be segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominates the market due to its advanced healthcare infrastructure, increased awareness of liver diseases, and the presence of key market players. Europe follows closely, while Asia-Pacific is anticipated to be the fastest-growing region due to the increasing prevalence of underlying conditions, improving healthcare infrastructure, and rising healthcare expenditures in the region.

Future Outlook

The ascites market is expected to continue growing in the coming years, primarily driven by the increasing prevalence of underlying conditions, advancements in diagnostic and treatment technologies, and improved access to healthcare services. As new technologies emerge and healthcare systems continue to evolve, the market may experience increased access to treatment and improved patient outcomes, resulting in a more robust and dynamic ascites market.

Key Players in the Global Ascites Market

The report gives an in-depth analysis of the key players involved in the ascites market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Becton, Dickinson and Company
  • BioVie Inc
  • Sequana Medical NV
  • Sanofi Inc
  • F. Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Merck & Co., Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ascites Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ascites Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Ascites Epidemiology (2016-2031)
5.3 Europe Ascites Epidemiology (2016-2031)
5.4 Asia-Pacific Ascites Epidemiology (2016-2031)
5.5 Latin America Ascites Epidemiology (2016-2031)
5.6 Middle East & Africa Ascites Epidemiology (2016-2031)
6 Global Ascites Market Overview
6.1 Global Ascites Market Historical Value (2016-2022)
6.2 Global Ascites Market Forecast Value (2023-2031)
7 Global Ascites Market Landscape
7.1 Ascites: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ascites: Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Diagnosis
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
8 Ascites Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Ascites Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Ascites Market Segmentation
11.1 Global Ascites Market by Treatment
11.1.1 Market Overview
11.1.2 Medicinal Therapy Diuretics Antibiotics
11.1.3 Surgery
11.1.4 Paracentesis
11.1.5 Others
11.2 Global Ascites Market by Diagnosis
11.2.1 Market Overview
11.2.2 Ultrasound
11.2.3 CT Scan
11.2.4 MRI
11.2.5 Blood Test
11.2.6 Laparoscopy
11.2.7 Angiography
11.2.8 Others
11.3 Global Ascites Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Global Ascites Market by End User
11.4.1 Market Overview
11.4.2 Hospitals & Clinics
11.4.3 Research and Academic Laboratories
11.4.4 Others
11.5 Global Ascites Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Ascites Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Ascites Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Ascites Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Ascites Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Ascites Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Becton, Dickinson and Company
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 BioVie Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sequana Medical NV
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Teva Pharmaceutical Industries Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Sun Pharmaceutical Industries Ltd.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Merck & Co., Inc.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Ascites - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Becton, Dickinson and Company
  • Biovie Inc.
  • Sequana Medical Nv
  • Sanofi Inc.
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co. Inc.
  • Wockhardt



Table Information